sulfasalazine has been researched along with Epilepsy in 6 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a case of seizures with acute encephalopathy in a female patient under sulfasalazine treatment for polyarthritis." | 3.71 | [Sulfasalazine neurotoxicity]. ( Chadenat, ML; Dechy, H; Dorra, M; Dupont, C; Morelon, S; Raffin-Sanson, ML; Rouveix, E, 2001) |
| "Sulfasalazine (SAS) is an US Food and Drug Administration (FDA)-approved drug for the treatment of Crohn disease that has been shown to inhibit the cystine/glutamate antiporter system xc- (SXC) and decrease tumor-associated seizures." | 1.51 | Sulfasalazine decreases mouse cortical hyperexcitability. ( Alcoreza, O; Bouslog, A; Campbell, SL; Savoia, A; Sontheimer, H; Tewari, BP, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Alcoreza, O | 2 |
| Jagarlamudi, S | 1 |
| Savoia, A | 2 |
| Campbell, SL | 3 |
| Sontheimer, H | 4 |
| Pietropaoli, S | 1 |
| Leonetti, A | 1 |
| Cervetto, C | 1 |
| Venturini, A | 1 |
| Mastrantonio, R | 1 |
| Baroli, G | 1 |
| Persichini, T | 1 |
| Colasanti, M | 1 |
| Maura, G | 1 |
| Marcoli, M | 1 |
| Mariottini, P | 1 |
| Cervelli, M | 1 |
| Tewari, BP | 1 |
| Bouslog, A | 1 |
| Buckingham, SC | 1 |
| Haas, BR | 1 |
| Montana, V | 1 |
| Robel, S | 1 |
| Ogunrinu, T | 1 |
| Bridges, RJ | 1 |
| Chadenat, ML | 1 |
| Morelon, S | 1 |
| Dupont, C | 1 |
| Dechy, H | 1 |
| Raffin-Sanson, ML | 1 |
| Dorra, M | 1 |
| Rouveix, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial Combining Sulfasalazine and Gamma Knife Radiosurgery for Recurrent Glioblastoma[NCT04205357] | Phase 1 | 24 participants (Actual) | Interventional | 2020-03-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for sulfasalazine and Epilepsy
| Article | Year |
|---|---|
Sulfasalazine decreases astrogliosis-mediated seizure burden.
Topics: Animals; Antiporters; Electroencephalography; Epilepsy; Gliosis; Glutamic Acid; Humans; Mice; Seizur | 2022 |
Glutamate Excitotoxicity Linked to Spermine Oxidase Overexpression.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Amino Acid Transport System y+; Animals; Behavior, Animal; Brain; Deoxy | 2018 |
Sulfasalazine decreases mouse cortical hyperexcitability.
Topics: Animals; Anticonvulsants; Brain; Disease Models, Animal; Epilepsy; Excitatory Postsynaptic Potential | 2019 |
Glutamate release by primary brain tumors induces epileptic activity.
Topics: Amino Acid Transport System y+; Analysis of Variance; Animals; Brain Neoplasms; Cell Transplantation | 2011 |
Sulfasalazine for brain cancer fits.
Topics: Amino Acid Transport System y+; Animals; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Ep | 2012 |
[Sulfasalazine neurotoxicity].
Topics: Acute Disease; Adult; Antirheumatic Agents; Arthritis; Encephalitis; Epilepsy; Female; Humans; Sulfa | 2001 |